New glucose tracking could catch transplant trouble early
NCT ID NCT07470593
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 36 people with type 1 diabetes who have received a pancreatic islet transplant. Researchers will use continuous glucose monitors to see if a measure called 'Time in Tight Range' can detect early loss of graft function. The goal is to find a simple way to spot problems before they become serious.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to a standardized method for early detection of islet graft failure, helping doctors intervene sooner.
- What could go wrong
- This is a small observational study (36 people) that only measures a glucose parameter, not a treatment. It may not prove useful in real-world settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INSULIN-DEPENDENT DIABETES SECONDARY TO CYSTIC FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hopitaux Universitaires de Strasbourg
RECRUITINGStrasbourg, 67200, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Open-Source insulin systems match commercial ones without meal announcements?
- A glucose Monitor's second chance: can it tame type 1 diabetes in High-Risk teens?
- AI takes the wheel: could a smart algorithm optimize insulin pumps from home?
- Could a metabolic modulator help people with type 1 diabetes use insulin better?
- Immune cell study may unlock kidney protection in type 1 diabetes
- Could an arthritis drug stop type 1 diabetes before it starts?